EUVIMEDEUVIMED entdecken
Crossref

Development and Validation of an UPLC‐QqQ MS/MS Method for the Determination of Daraxonrasib, a New pan‐KRAS Inhibitor, in Dog Plasma and Whole Blood and Its Application to Pharmacokinetic Studies

Wentao Zhang, Yanzi Liu, Ali Fan, Xuan Geng iD

Biomedical Chromatography · 2026-12 · 40 (12)

DOI: 10.1002/bmc.70647 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 27.10.2026. Verfasst von Wentao Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Xuzhou Central Hospital, Southeast University, Xuzhou, Jiangsu Province, China. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Chromatography, High Pressure Liquid, Proto-Oncogene Proteins p21(ras). Die Arbeit nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Daraxonrasib, an orally administered pan‐RAS inhibitor, is undergoing clinical evaluation for pancreatic ductal adenocarcinoma, colorectal cancer, and non‐small cell lung cancer. Defining its pharmacokinetic profile is therefore critical for ongoing progress. Accordingly, a simple and sensitive UPLC‐QqQ‐MS/MS assay was developed and validated to quantify daraxonrasib in canine plasma and whole blood. Proteins were precipitated with a 20:80 (v/v) acetonitrile–methanol solution containing 0.1% formic acid. Chromatographic separation was performed on a Waters ACQUITY BEH C18 column (50 mm × 2.1 mm, 1.7 μm). The mobile phase consisted of 2 mM ammonium acetate and acetonitrile, each containing 0.1% formic acid, delivered at 0.4 mL/min. Multiple reaction monitoring transitions for daraxonrasib and the internal standard were m/z 811.5 → 680.3 and m/z 724.4 → 396.2, respectively. Calibration standards showed linear response from 1.0 to 1000 ng/mL ( r > 0.998). The assay met validation criteria for specificity, recovery, limit of quantification, accuracy, and precision. Finally, this validated method was applied to a dog pharmacokinetic study of daraxonrasib. This report outlines the drug's pharmacokinetic characteristics and supports its continued development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tandem Mass SpectrometryChromatography, High Pressure LiquidProto-Oncogene Proteins p21(ras)Linear ModelsAnimalsDogsPiperazines

Stichwörter der Autor:innen

UPLC‐QqQ‐MS/MSbioavailabilitydaraxonrasibpan‐KRASpharmacokinetics

Substanzen

daraxonrasibProto-Oncogene Proteins p21(ras)Piperazines

Autor:innen und Institutionen

  • Department of Gastrointestinal Surgery, Xuzhou Central Hospital, Southeast University, Xuzhou, Jiangsu Province, China.
  • College of Chemistry and Materials Science, Hebei University, Baoding, Hebei Province, China.
  • TriApex Laboratories Co. Ltd, Nanjing, Jiangsu Province, China.

ORCID-Profile: Xuan Geng

Zitieren

APA

Zhang, W., Liu, Y., Fan, A., & Geng, X. (2026). Development and Validation of an UPLC‐QqQ MS/MS Method for the Determination of Daraxonrasib, a New pan‐KRAS Inhibitor, in Dog Plasma and Whole Blood and Its Application to Pharmacokinetic Studies. Biomedical Chromatography, 40(12). https://doi.org/10.1002/bmc.70647

Vancouver

Zhang W, Liu Y, Fan A, Geng X. Development and Validation of an UPLC‐QqQ MS/MS Method for the Determination of Daraxonrasib, a New pan‐KRAS Inhibitor, in Dog Plasma and Whole Blood and Its Application to Pharmacokinetic Studies. Biomedical Chromatography. 2026;40(12). doi:10.1002/bmc.70647

BibTeX
@article{Zhang2026,
  author = {Zhang, Wentao and Liu, Yanzi and Fan, Ali and Geng, Xuan},
  title = {Development and Validation of an UPLC‐QqQ MS/MS Method for the Determination of Daraxonrasib, a New pan‐KRAS Inhibitor, in Dog Plasma and Whole Blood and Its Application to Pharmacokinetic Studies},
  journal = {Biomedical Chromatography},
  year = {2026},
  volume = {40},
  number = {12},
  doi = {10.1002/bmc.70647}
}
Kostenlos starten →